Viking has started Phase 3 trials of oral VK2735. Understand the SUNRISE design, earlier findings, and questions still awaiting answers.
On October 14, 2026, Viking Therapeutics announced the start of SUNRISE, its Phase 3 program for oral VK2735. The candidate drug activates both GLP-1 and GIP receptors and is being studied as a once-daily oral treatment for weight management.
According to Viking’s announcement, SUNRISE includes two randomized, double-blind, placebo-controlled trials conducted across multiple centers. Each trial targets 560 adults and will treat participants for 68 weeks. Those enrollment figures are targets rather than completed recruitment totals.
The studies address distinct populations:
Both studies will compare three daily doses of oral VK2735 with placebo. The main outcome is percentage change in body weight from baseline after 68 weeks. Secondary measures include the proportions reaching at least 5%, 10%, 15%, or 20% weight reduction.
That design gives the announcement a specific meaning: Viking is beginning longer-duration testing of its oral candidate in separate populations. The central question is how the treatment performs over the study period, including both weight outcomes and safety.
Readers following the broader program can also see our coverage of other VK2735 dosing research. This announcement concerns the once-daily oral formulation.
Viking describes VK2735 as a dual GLP-1/GIP receptor agonist. In plain language, an agonist activates a biological target called a receptor. “Dual” means the candidate acts on both named receptor systems rather than only one.
Think of receptors as receivers for biological signals. The mechanism described in Viking’s announcement is about activating those receivers. The clinical trials then measure what that activity means for outcomes such as body weight and adverse events.
Two separate features are easy to mix together here. GLP-1/GIP receptor activation describes the drug’s biological strategy. Oral delivery describes how it is taken. A tablet is a route of administration, not a different standard of evidence.
The practical question is whether this combination of mechanism and delivery produces meaningful weight change with an acceptable burden of side effects. That is why the trial results matter more than the mechanism’s name alone. A clear biological rationale is a starting point for testing, not the finished clinical answer.
For readers interested in a pill rather than an injection, keeping those questions separate is useful. Preference concerns the treatment format. Evidence concerns what happens when people receive that treatment over time.
Investing.com’s headline framed the development as the start of Phase 3 trials. That is the important distinction to retain when reading coverage about an obesity pill: the announced milestone concerns clinical development, not a product launch.
The appeal of an oral option can make the story feel immediately relevant to treatment choices. But the announcement contained no SUNRISE efficacy or safety results. Viking also cautioned that earlier clinical results may not be reproduced in later testing.
Several other practical questions remain unanswered in the release. It provides no price or approval timeline. It also gives no projected dates for enrollment completion or data readout, so the 68-week treatment period should not be treated as a countdown to public results or availability.
Viking CEO Brian Lian said the company believes a daily oral option could offer flexibility and potentially support adherence. That is an expectation, not a demonstrated SUNRISE outcome. A preference for tablets does not by itself establish effectiveness, tolerability, suitability, or sustained treatment use.
The comparator also sets the scope of the evidence. These studies compare VK2735 with placebo rather than another active weight-management medicine. Their results will therefore address a different question from a direct comparison between treatments.
At WeightRestart, we believe the useful distinction is between a promising research direction and evidence ready to inform personal care. For someone considering treatment now, the practical step is to discuss available options with a qualified clinician rather than make plans around this candidate’s development schedule.
The SUNRISE program follows Viking’s 2025 report of its Phase 2 VENTURE-Oral results. Those company-reported findings provide the background for the new studies and deserve a careful reading on their own terms.
Viking reported dose-dependent mean weight reductions of up to 12.2% after 13 weeks. “Mean” refers to a group average. “Up to” identifies the highest reported result across the dose groups rather than a result shared by every group or every participant.
Those words are not technical clutter. They determine what the number describes. Reading the figure as “VK2735 produces 12.2% weight loss” would remove the study duration and dose-group context while turning a reported average into an individual expectation.
Viking also reported that up to 97% of participants in some treated dose groups reached at least 5% weight loss, compared with 10% of placebo recipients. This is a different type of measurement from average weight change. It describes how many participants crossed a specified threshold.
The two measures answer related but distinct questions. An average summarizes the group’s weight change. A threshold result shows the proportion reaching a particular level of change, without describing every participant’s full experience.
For anyone comparing study headlines, the practical reading habit is to keep the population and duration attached to each percentage. Then identify whether the figure is an average or a threshold result. Our discussion of reading trial percentages in context uses that same evidence-first approach.
In its Phase 2 report, Viking said 98% of drug-related treatment-emergent adverse events were mild or moderate. Gastrointestinal events were the most commonly observed. The announcement did not provide discontinuation rates.
The denominator matters here. That 98% describes the reported drug-related events, not the proportion of participants who experienced no side effects. It should not be translated into a claim that almost everyone found the treatment easy to take.
Similarly, describing an event as mild or moderate does not tell readers whether someone continued treatment. Weight change and the experience of staying on treatment are separate parts of the clinical picture. A useful assessment keeps both in view rather than allowing the largest weight-loss figure to dominate.
The next meaningful updates should make the trial’s benefit-and-risk picture easier to judge. Useful reporting would bring the main weight outcome together with the distribution of responses and the experience of participants throughout treatment.
In particular, watch for:
Viking says it is also studying oral VK2735 for maintenance dosing and developing an injectable formulation through its Phase 3 VANQUISH program. Those efforts raise additional questions about how different formulations might eventually fit into care. The company’s suggested induction or maintenance roles remain possibilities under investigation.
For the SUNRISE program to inform routine practice, the evidence will need to support a clear account of benefits and risks over the planned treatment period. Any personal treatment decision would then require consideration of that evidence in the context of an individual’s health and circumstances.
What deserves attention next is not simply another large weight-loss number. It is whether the longer-duration findings show a consistent treatment effect alongside a sufficiently clear safety and tolerability profile. That fuller picture will determine how much this oral candidate adds to weight-management care.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
